Carl B Rebhun1, Eric M Moult2, Stefan B Ploner3, Carlos Moreira Neto1, A Yasin Alibhai1, Julia Schottenhamml3, Byungkun Lee2, WooJhon Choi2, Fareed A Rifai4, Mary W Tam1, Lennart Husvogt3, Caroline R Baumal1, Andre J Witkin1, Andreas Maier5, Philip J Rosenfeld6, Jay S Duker1, James G Fujimoto2, Nadia K Waheed7. 1. New England Eye Center, Tufts Medical Center, Boston, Massachusetts. 2. Department of Electrical Engineering and Computer Science, and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts. 3. Department of Electrical Engineering and Computer Science, and Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, Massachusetts; Pattern Recognition Laboratory, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany. 4. University of South Alabama College of Medicine, Mobile, Alabama. 5. Pattern Recognition Laboratory, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany. 6. Bascom Palmer Eye Institute, Miami, Florida. 7. New England Eye Center, Tufts Medical Center, Boston, Massachusetts. Electronic address: nadiakwaheed@gmail.com.
Abstract
PURPOSE: Longitudinally visualizing relative blood flow speeds within choroidal neovascularization (CNV) may provide valuable information regarding the evolution of CNV and the response to vascular endothelial growth factor (VEGF) inhibitors. DESIGN: Retrospective, longitudinal case series conducted at the New England Eye Center. PARTICIPANTS: Patients with either treatment-naïve or previously treated CNV secondary to neovascular age-related macular degeneration. METHODS: Optical coherence tomography angiography (OCTA) was performed using a 400-kHz, 1050-nm swept-source OCT system with a 5-repeat B-scan protocol. Variable interscan time analysis (VISTA) was used to compute relative flow speeds from pairs of B-scans having 1.5- and 3.0-ms separations; VISTA signals then were mapped to a color space for display. MAIN OUTCOME MEASURES: Quantitative outcomes included OCTA-based area and volume measurements of CNV at initial and follow-up visits. Qualitative outcomes included VISTA OCTA analysis of relative blood flow speeds, along with analysis of contraction, expansion, densification, and rarefication of CNV. RESULTS: Seven eyes of 6 patients (4 women and 2 men) with neovascular age-related macular degeneration were evaluated. Two eyes were treatment naïve at the initial visit. Choroidal neovascularization in all eyes at each visit showed relatively higher flow speeds in the trunk, central, and larger vessels and lower flow speed in the small vessels, which generally were located at the periphery of the CNV complex. Overall, the CNV appeared to expand over time despite retention of good visual acuity in all patients. In the treatment-naïve patients, slower-flow-speed vessels contracted with treatment, whereas the larger vessels with higher flow speed remained constant. CONCLUSIONS: Variable interscan time analysis OCTA allows for longitudinal observations of relative blood flow speeds in CNV treated with anti-VEGF intravitreal injections. A common finding in this study is that the main trunk and larger vessels seem to have relatively faster blood flow speeds compared with the lesions' peripheral vasculature. Moreover, an overall growth of chronically treated CNV was seen despite retention of good visual acuity. The VISTA framework may prove useful for developing clinical end points, as well as for studying hemodynamics, disease pathogenesis, and treatment response.
PURPOSE: Longitudinally visualizing relative blood flow speeds within choroidal neovascularization (CNV) may provide valuable information regarding the evolution of CNV and the response to vascular endothelial growth factor (VEGF) inhibitors. DESIGN: Retrospective, longitudinal case series conducted at the New England Eye Center. PARTICIPANTS: Patients with either treatment-naïve or previously treated CNV secondary to neovascular age-related macular degeneration. METHODS: Optical coherence tomography angiography (OCTA) was performed using a 400-kHz, 1050-nm swept-source OCT system with a 5-repeat B-scan protocol. Variable interscan time analysis (VISTA) was used to compute relative flow speeds from pairs of B-scans having 1.5- and 3.0-ms separations; VISTA signals then were mapped to a color space for display. MAIN OUTCOME MEASURES: Quantitative outcomes included OCTA-based area and volume measurements of CNV at initial and follow-up visits. Qualitative outcomes included VISTA OCTA analysis of relative blood flow speeds, along with analysis of contraction, expansion, densification, and rarefication of CNV. RESULTS: Seven eyes of 6 patients (4 women and 2 men) with neovascular age-related macular degeneration were evaluated. Two eyes were treatment naïve at the initial visit. Choroidal neovascularization in all eyes at each visit showed relatively higher flow speeds in the trunk, central, and larger vessels and lower flow speed in the small vessels, which generally were located at the periphery of the CNV complex. Overall, the CNV appeared to expand over time despite retention of good visual acuity in all patients. In the treatment-naïve patients, slower-flow-speed vessels contracted with treatment, whereas the larger vessels with higher flow speed remained constant. CONCLUSIONS: Variable interscan time analysis OCTA allows for longitudinal observations of relative blood flow speeds in CNV treated with anti-VEGF intravitreal injections. A common finding in this study is that the main trunk and larger vessels seem to have relatively faster blood flow speeds compared with the lesions' peripheral vasculature. Moreover, an overall growth of chronically treated CNV was seen despite retention of good visual acuity. The VISTA framework may prove useful for developing clinical end points, as well as for studying hemodynamics, disease pathogenesis, and treatment response.
Authors: Woo June Choi; Wan Qin; Chieh-Li Chen; Jingang Wang; Qinqin Zhang; Xiaoqi Yang; Bruce Z Gao; Ruikang K Wang Journal: Biomed Opt Express Date: 2016-06-20 Impact factor: 3.732
Authors: Simon S Gao; Li Liu; Steven T Bailey; Christina J Flaxel; David Huang; Dengwang Li; Yali Jia Journal: J Biomed Opt Date: 2016-07-01 Impact factor: 3.170
Authors: Miao Zhang; Thomas S Hwang; J Peter Campbell; Steven T Bailey; David J Wilson; David Huang; Yali Jia Journal: Biomed Opt Express Date: 2016-02-09 Impact factor: 3.732
Authors: Ursula Schmidt-Erfurth; Peter K Kaiser; Jean-François Korobelnik; David M Brown; Victor Chong; Quan Dong Nguyen; Allen C Ho; Yuichiro Ogura; Christian Simader; Glenn J Jaffe; Jason S Slakter; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Olaf Sowade; Oliver Zeitz; Christiane Norenberg; Rupert Sandbrink; Jeffrey S Heier Journal: Ophthalmology Date: 2013-09-29 Impact factor: 12.079
Authors: Malvika Arya; Ramy Rashad; Osama Sorour; Eric M Moult; James G Fujimoto; Nadia K Waheed Journal: Expert Rev Med Devices Date: 2018-11-22 Impact factor: 3.166
Authors: Mengxi Shen; Qinqin Zhang; Jin Yang; Hao Zhou; Zhongdi Chu; Xiao Zhou; William Feuer; Xiaoshuang Jiang; Yingying Shi; Luis de Sisternes; Mary K Durbin; Ruikang K Wang; Giovanni Gregori; Philip J Rosenfeld Journal: Invest Ophthalmol Vis Sci Date: 2021-05-03 Impact factor: 4.799
Authors: Eric M Moult; Agha Yasin Alibhai; Carl Rebhun; ByungKun Lee; Stefan Ploner; Julia Schottenhamml; Lennart Husvogt; Caroline R Baumal; Andre J Witkin; Andreas Maier; Jay S Duker; Phillip J Rosenfeld; Nadia K Waheed; James G Fujimoto Journal: Retina Date: 2020-03 Impact factor: 3.975
Authors: Omer Trivizki; Eric M Moult; Liang Wang; Prashanth Iyer; Yingying Shi; Giovanni Gregori; William Feuer; James G Fujimoto; Philip J Rosenfeld Journal: Invest Ophthalmol Vis Sci Date: 2022-01-03 Impact factor: 4.799